Clinilabs, Inc. Selected for A Phase 1 Study of an Investigational Patch Medication

Published: May 25, 2011

New York, NY (May 24, 2011) – Clinilabs, a full-service contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase 1 clinical research study of an investigational patch medication.

The study will test the efficacy of a patch form of medication as compared to the oral form of the same medication which is currently on the market. Clinilabs is operated in New York City, a hub of academic medical centers and home to a racially diverse population of more than 19 million potential research subjects. “As we continually expand our database of research volunteers, we are better able to enroll for important studies that require the inclusion of healthy volunteers as well as clinical populations” states Jeanine Estrada, Director of Business Development. “There is no other city in the world that offers such access to clinical trial participants,” she adds.

Clinilabs is currently enrolling healthy male and female volunteers to take part in the study. The Company also is seeking post-menopausal women and those with depression, insomnia, sleep apnea, COPD, psoriasis, cognitive impairment, hepatitis C, diabetes, and other conditions for participation in current and future studies. Individuals in the New York City Metro area who would like to participate can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting

About Clinilabs Inc.

Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit

Back to news